<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1726-8958</journal-id>
<journal-title><![CDATA[Revista Médica La Paz]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. La Paz]]></abbrev-journal-title>
<issn>1726-8958</issn>
<publisher>
<publisher-name><![CDATA[Colegio Médico de La Paz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1726-89582024000300101</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[ORBITOPATIA TIROIDEA]]></article-title>
<article-title xml:lang="en"><![CDATA[THYROID ORBITOPATHY]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[Kelly]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urquizo Ayala]]></surname>
<given-names><![CDATA[Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínicas Universitario Unidad de Endocrinología y Nutrición ]]></institution>
<addr-line><![CDATA[La Paz ]]></addr-line>
<country>Bolivia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Clínicas Universitario Unidad de Medicina Interna ]]></institution>
<addr-line><![CDATA[La Paz ]]></addr-line>
<country>Bolivia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>30</volume>
<numero>3</numero>
<fpage>101</fpage>
<lpage>105</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1726-89582024000300101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1726-89582024000300101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1726-89582024000300101&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La orbitopatía tiroidea (OT), también llamada enfermedad de Graves orbitaria u oftalmopatía de Graves, es una manifestación de una enfermedad autoinmune relacionada con el hipertiroidismo, especialmente con la enfermedad de Graves, aunque también puede manifestarse en casos de hipotiroidismo autoinmune. Llevamos a cabo una revisión acerca del diagnóstico y terapia de esta enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Thyroid orbitopathy (OT), also called orbital Graves&#8217; disease or Graves&#8217; ophthalmopathy, is a manifestation of an autoimmune disease related to hyperthyroidism, especially Graves&#8217; disease, although it can also manifest in cases of autoimmune hypothyroidism. We conducted a review of the diagnosis and therapy of this disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Orbitopatía]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad de Graves]]></kwd>
<kwd lng="es"><![CDATA[hipertiroidismo]]></kwd>
<kwd lng="en"><![CDATA[Orbitopathy]]></kwd>
<kwd lng="en"><![CDATA[Graves&#8217; disease]]></kwd>
<kwd lng="en"><![CDATA[hyperthyroidism]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hegedüs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thyroid-associated ophthalmopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1552-65</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartalena]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tanda]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Orbital imaging in Graves' orbitopathy a practical overview]]></article-title>
<source><![CDATA[J Endocrinol Invest]]></source>
<year>2020</year>
<volume>43</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1007-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartalena]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Graves' orbitopathy recommendations of the European Group on Graves' Orbitopathy (EUGOGO)]]></article-title>
<source><![CDATA[J Endocrinol Metab]]></source>
<year>2023</year>
<volume>108</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>233-43</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hegedüs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of disease the pathophysiology of Graves' disease and orbitopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>389</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>633-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo de la oftalmopatía tiroidea:nuevas opciones y tratamientos específicos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratamientos avanzados en endocrinología]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Ciudad ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Nacional]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoterapia en la oftalmopatía tiroidea:nuevos avances y terapias específicas]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Avances en Endocrinología e Inmunoterapia. 2da ed]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Ciudad ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Nacional]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoterapia en la oftalmopatía tiroidea evaluación de teprotumumab, rituximab y tocilizumab]]></article-title>
<source><![CDATA[Rev Endocrinol Clin]]></source>
<year>2024</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-34</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento con esteroides en orbitopatía tiroidea:corticoterapia intravenosa y combinaciones terapéuticas]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Terapias actuales en endocrinología ocular]]></source>
<year>2024</year>
<edition>3ra ed.</edition>
<publisher-loc><![CDATA[Ciudad ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Nacional]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticoterapia en la oftalmopatía tiroidea eficacia de la administración intravenosa y terapias combinadas]]></article-title>
<source><![CDATA[Rev Endocrinol Clin]]></source>
<year>2024</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>145-56</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Douglas]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Kahaly]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sile]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Perdok]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teprotumumab for the treatment of active thyroid eye disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>341-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Douglas]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Holt]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy and safety of teprotumumab for thyroid eye disease a 2-year extension study]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2023</year>
<volume>130</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-96</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez-Moreiras]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Reino]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maneiro]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-Pampin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Romo Lopez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Garcia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tocilizumab in Graves orbitopathy a randomized, double-blind, placebo-controlled clinical trial]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2018</year>
<volume>103</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>488-95</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hegedüs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thyroid-associated ophthalmopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1552-65</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartalena]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kahaly]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baldeschi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dayan]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Eckstein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marcocci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2021</year>
<volume>185</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rendell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Orbital decompression surgery in thyroid eye disease current perspectives]]></article-title>
<source><![CDATA[Clin Ophthalmol]]></source>
<year>2023</year>
<volume>17</volume>
<page-range>567-76</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halperin]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Wazer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<source><![CDATA[Perez and Brady's Principles and Practice of Radiation Oncology]]></source>
<year>2018</year>
<edition>7</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams &amp; Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponto]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Diana]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Binder]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Matheis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pitz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeiffer]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical relevance of thyroidstimulating immunoglobulins in Graves' orbitopathy a multicenter study]]></article-title>
<source><![CDATA[Am J Ophthalmol.]]></source>
<year>2018</year>
<volume>189</volume>
<page-range>135-42</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stan]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Garrity]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Graves' orbitopathy clinical management and advances in therapy]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2022</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-24</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of advanced imaging techniques in the diagnosis and management of thyroid eye disease]]></article-title>
<source><![CDATA[Ophthalmic Res]]></source>
<year>2023</year>
<volume>61</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>321-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
